A clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways.
- Year invested 2009
- Investment Stage Early
- Sectors
- Investment Status Current
- Website sagimet.com
- Company Status Private